Smartphones Spot Ocular Malignancies

• July 2, 2026

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

• July 1, 2026

• 1 min

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer

• by John Scholler, Ai Song, Mansi Deshmukh, Decheng Song, Khatuna Gabunia, Mei Ji, Shimin Liu, Ting-Jia Fan, Gayathri Gulendran, Carl H. June, Don L. Siegel

• July 1, 2026

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

• July 1, 2026

• 1 min